Canada Leads G7 Nations in Approving Generic Semaglutide, Promising Major Cost Relief for Diabetes Patients

Canada has taken a historic step in making diabetes treatment more accessible, becoming the first G7 country to authorize a generic version of semaglutide the active ingredient found in blockbuster drugs like Ozempic, Wegovy, and Mounjaro.

Health Canada has now approved two generic versions of the medication in quick succession. The first, manufactured by India-based Dr. Reddy’s Laboratories, received the green light Tuesday night. Hot on its heels came approval for a second version, this one produced by Apotex, a homegrown Canadian pharmaceutical company. Seven additional submissions from other manufacturers are currently under review, with regulatory decisions expected to roll out over the coming weeks and months.

Both approved generics are indicated for the once-weekly treatment of Type 2 diabetes in adults the same use case as the original brand-name products.

For patients who may be wary of switching from a trusted brand-name medication to a generic alternative, Canadian medical experts are offering reassurance.

Dr. Hertzel Gerstein, a diabetes physician and professor in the department of medicine at McMaster University, explained that Health Canada’s approval process for generics is anything but a rubber stamp. The agency conducts a thorough review to ensure that the chemical composition of a generic drug is as close to the original as scientifically possible.

“The fact that they’ve approved it should reassure most people,” Gerstein noted, adding that patients can expect “a very similar, if not identical, effect” compared to the brand-name versions they may already be using.

Perhaps the most significant implication of these approvals is the potential for a dramatic reduction in out-of-pocket costs something that could be life-changing for thousands of Canadians who have been priced out of treatment altogether.

Currently, Ozempic can cost between $200 and $450 per month, depending on the province. Mounjaro runs between $300 and $550 monthly, while Wegovy carries a list price of approximately $400 per month, or over $5,000 annually. For many patients, these figures place consistent treatment firmly out of reach.

Generic medications, Health Canada has noted, are typically priced 45 to 90 per cent below their brand-name counterparts.

Dana Small, a professor of neurology and neurosurgery at McGill University, put that in plain terms: “The numbers I’ve heard are anywhere from like $40 to $80,” she told Global News. “That’s a major decrease in cost.”

With more generic submissions in the pipeline and a regulatory body that appears ready to move swiftly, Canada finds itself at what could be a genuine turning point in how semaglutide-based treatment is accessed and afforded. Whether this momentum translates into real relief for patients will depend on how quickly these products reach pharmacy shelves and how insurers and provincial drug plans respond to the new pricing landscape.

For now, Canada has made its mark as a first mover among the world’s wealthiest nations and for millions living with Type 2 diabetes, that move could not have come soon enough.